Hypoactive sexual desire disorder (HSDD), which emerged in the late 1970s with the rise of sexual therapy (listed in the Diagnostic and Statistical Manual of Mental Disorders), has gained increasing attention—promotion and a reaction of criticism—with the rise of the pharmaceutical industry’s influence in sexual research. The relationship of these categories has often been noted but largely unexplored, especially in the context of men’s HSDD. So far, research has focused more on female HSDD. Even the study by Segraves, K. B et al. (J Sex Marital Ther 17:55–58, 1991), involving 906 subjects (studied in a multisite pharmaceutical study) with a primary diagnosis of HSDD, found that: HSDD was much more common in females than in male subjects. Males diagnosed with HSDD were significantly older. Approximately 40% of subjects with a primary diagnosis of HSDD had a secondary diagnosis of arousal or orgasm disorders. But today, research has found otherwise.